Cover Image
Market Research Report
Product code 
630103

Transthyretin Amyloidosis (ATTR) - Competitive Landscape, Market Insights, Epidemiology and Market Forecast - 2027

Published: Pre-Order | DelveInsight Business Research LLP | 149 Pages | Delivery time: 2-10 business days

Price

Back to Top
Transthyretin Amyloidosis (ATTR) - Competitive Landscape, Market Insights, Epidemiology and Market Forecast - 2027
Published: Pre-Order
DelveInsight Business Research LLP
Content info: 149 Pages
Delivery time: 2-10 business days
  • ALL
  • Description
  • Table of Contents
Description

DelveInsight's "Transthyretin Amyloidosis (ATTR) - Competitive Landscape, Market Insights, Epidemiology and Market Forecast - 2027" Report provides an overview of the disease and market size of Transthyretin Amyloidosis for the seven major markets i.e., the United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. The Report also covers the overview, treatment practice and Transthyretin Amyloidosis forecasted epidemiology from 2018 to 2027 segmented by seven major markets.

Transthyretin Amyloidosis (ATTR) Product Profiles & Analysis

The drug chapter segment covers the complete analysis of marketed drugs, Phase III, Phase II, Phase 1 and Preclinical pipeline drugs. This division focuses on the recent breakthroughs like clinical development analysis, agreements and collaborations, clinical trial details, allotted designations, published results, pharmacological effects, patent expiry, and expected launch timings.

Epidemiology Insights

The report provides a comprehensive account of the total patient pool, diagnosed cases and potential patient pool eligible for the treatment. It also includes the explanation of changing trends of epidemiology after evaluating numerous studies, survey reports and views of key opinion leaders. The Report provides the 10 years forecast from 2018 to 2027 segmented by seven major markets, enabling to understand the potential of the Transthyretin Amyloidosis in the respective markets. The epidemiology data is presented with graphs and tables to provide a clear assessment of the landscape.

Transthyretin Amyloidosis (ATTR) Market Outlook

The report's market outlook delivers an understanding of the country-specific revenue and share by analyzing the performance of the current therapies and potential uptake of new products. The in-depth analysis helps to recognize the growing demand of the market by evaluating the annual cost of therapy, compliance rate, competition with other therapies, covered patient segment, the impact of emerging technology in the forecast period. The views from the key opinion leaders adds more value to the analysis. This segment provides the relevant graphs and tables to have an effective outline of the Transthyretin Amyloidosis (ATTR) market.

Emerging Therapies Analysis

Transthyretin Amyloidosis treatment landscape is set to change by the imminent entry of major players such as Alnylam Pharmaceuticals, Corino Therapeutics, Sanofi Aventis and Ionis Pharmaceuticals, which are focusing on developing therapies that are expected to create a positive impact on the market of this disease. Out of these companies, Patisiran of Alnylam Pharmaceuticals- Sanofi is expected to enter the market in June 2018 as a standard treatment of TTR-FAP, followed by the launch of Inotersen by Ionis Pharmaceuticals Inc. Apart from these, CRX-1008 of Corino Therapeutics Inc. is expected to enter market by 2023, however may face tough competition to grab market share, due to the presence of drugs already approved.

It comprehensively includes:

The descriptive overview of the Transthyretin Amyloidosis, explaining its pathophysiology, diagnostic approaches and treatment algorithm

An insight into the epidemiology of the disease and its treatment in the 7 MM, covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan

A comprehensive account of both the current and emerging therapies, assessing the impact of new therapies on the current treatment landscape

The detailed global historical and forecasted Transthyretin Amyloidosis market including the drug outreach in 7 MM

It will help in developing business strategies by understanding trends shaping and driving the global Transthyretin Amyloidosis market

Key Strengths

10 Years Forecast (2018-2027)

7MM Coverage

Epidemiology Subtype Segmentation

Key Cross Competition

Market Size by Therapies

Complete Pipeline Portfolio

Key Assessments

Pipeline Product Profiles

Key Products and Key Players

Market Drivers and Barriers

Reasons to buy:

The report will help in developing business strategies by understanding trends shaping and driving the Transthyretin Amyloidosis market.

To understand the future market competition in the Transthyretin Amyloidosis market and Insight reviews of the key market drivers and barriers.

Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.

In-depth understanding of the pipeline development and recent happenings will provide a competitive edge over competitors.

Table of Contents
Product Code: DISR0027

Table of Contents

1. Report Introduction

2. Transthyretin Amyloidosis Market Overview at a Glance

  • 2.1. Market Share (%) Distribution of Transthyretin Amyloidosis in 2016
  • 2.2. Market Share (%) Distribution of Transthyretin Amyloidosis in 2027

3. Disease Background and Overview: Transthyretin-related amyloidosis

  • 3.1. Introduction
  • 3.2. Clinical aspects of ATTR
  • 3.3. Types of Transthyretin Amyloidosis
  • 3.4. Causes
  • 3.5. Symptoms
  • 3.6. Pathogenesis
  • 3.7. Diagnosis
    • 3.7.1. Tools for evaluating TTR-FAP progression

4. Epidemiology and Patient Population

  • 4.1. Key Findings
  • 4.2. Population and Forecast Parameters
  • 4.3. 7MM Diagnosed Prevalent Population of ATTR
  • 4.4. Type-specific Diagnosed Prevalent Population of ATTR in 7MM

5. Epidemiology by Country

  • 5.1. United States
    • 5.1.1. Diagnosed Prevalent Population of ATTR in the United States
    • 5.1.2. Type-specific Diagnosed Prevalent Population of hATTR in the United States
    • 5.1.3. Treatable cases of Transthyretin Amyloidosis in the United States
  • 5.2. European Union Five
    • 5.2.1. United Kingdom
      • 5.2.1.1. Diagnosed Prevalent Population of ATTR in the United Kingdom
      • 5.2.1.2. Type-specific Diagnosed Prevalent Population of hATTR in the United Kingdom
      • 5.2.1.3. Treatable cases of Transthyretin Amyloidosis in the United Kingdom
    • 5.2.2. Germany
      • 5.2.2.1. Diagnosed Prevalent Population of ATTR in Germany
      • 5.2.2.2. Type-specific Diagnosed Prevalent Population of hATTR in Germany
      • 5.2.2.3. Treatable cases of Transthyretin Amyloidosis in Germany
    • 5.2.3. Italy
      • 5.2.3.1. Diagnosed Prevalent Population of ATTR in Italy
      • 5.2.3.2. Type-specific Diagnosed Prevalent Population of hATTR in Italy
      • 5.2.3.3. Treatable cases of Transthyretin Amyloidosis in Italy
    • 5.2.4. Spain
      • 5.2.4.1. Diagnosed Prevalent Population of ATTR in Spain
      • 5.2.4.2. Type-specific Diagnosed Prevalent Population of hATTR in Spain
      • 5.2.4.3. Treatable cases of Transthyretin Amyloidosis in Spain
    • 5.2.5. France
      • 5.2.5.1. Diagnosed Prevalent Population of ATTR in France
      • 5.2.5.2. Type-specific Diagnosed Prevalent Population of hATTR in France
      • 5.2.5.3. Treatable cases of Transthyretin Amyloidosis in France
  • 5.3. Japan
    • 5.3.1. Diagnosed Prevalent Population of ATTR in Japan
    • 5.3.2. Type-specific Diagnosed Prevalent Population of hATTR in Japan
    • 5.3.3. Treatable cases of Transthyretin Amyloidosis in Japan

6. 7MM Diagnosed Surgery Cases of ATTR related Carpal Tunnel Syndrome

  • 6.1. Diagnosed Prevalent and Surgery Cases of ATTR related Carpal Tunnel Syndrome in the United States
  • 6.2. Diagnosed Prevalent and Surgery Cases of ATTR related Carpal Tunnel Syndrome in the United Kingdom
  • 6.3. Diagnosed Prevalent and Surgery Cases of ATTR related Carpal Tunnel Syndrome in Germany
  • 6.4. Diagnosed Prevalent and Surgery Cases of ATTR related Carpal Tunnel Syndrome in Italy
  • 6.5. Diagnosed Prevalent and Surgery Cases of ATTR related Carpal Tunnel Syndrome in France
  • 6.6. Diagnosed Prevalent and Surgery Cases of ATTR related Carpal Tunnel Syndrome in Japan

7. Current Treatment and Medical Practices

  • 7.1. Treatment Guidelines
    • 7.1.1. First European Consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy

8. Unmet Needs

9. Marketed Drugs

  • 9.1. Vyndaqel: Pfizer Inc.
    • 9.1.1. Drug Description
    • 9.1.2. Mechanism of Action
    • 9.1.3. Regulatory Milestones
    • 9.1.4. Advantages & Disadvantages
    • 9.1.5. Safety and Efficacy
    • 9.1.6. Ongoing trial description, 2017
    • 9.1.7. Product Profile

10. Therapeutics under Development by Companies

  • 10.1. Key Cross Competition
  • 10.2. Clinical Products (Phase III to Phase I]
    • 10.2.1. Patisiran: Alnylam Pharmaceuticals
      • 10.2.1.1. Regulatory Milestones
      • 10.2.1.2. Other development activities
      • 10.2.1.3. Clinical Development
      • 10.2.1.4. Clinical Trials Information
      • 10.2.1.5. Safety and Efficacy
      • 10.2.1.6. Product Profile
    • 10.2.2. Inotersen: Ionis Pharmaceuticals Inc.
      • 10.2.2.1. Regulatory Milestones
      • 10.2.2.2. Other development activities
      • 10.2.2.3. Clinical Development
      • 10.2.2.4. Clinical Trials Information
      • 10.2.2.5. Safety and Efficacy
      • 10.2.2.6. Product Profile
    • 10.2.3. CRX-1008: Corino Therapeutics Inc.
      • 10.2.3.1. Regulatory Milestones
      • 10.2.3.2. Other development activities
      • 10.2.3.3. Clinical Development
      • 10.2.3.4. Clinical Trials Information
      • 10.2.3.5. Safety and Efficacy
      • 10.2.3.6. Product Profile

To be continued in the report...

  • 10.3. Non-Clinical Products
    • 10.3.1. NPT189: Proclara Bioscience
      • 10.3.1.1. Drug Description
      • 10.3.1.2. Pre-Clinical results
      • 10.3.1.3. Other development activities
      • 10.3.1.4. Product Profile
    • 10.3.2. LUNAR-101: Arcturus Therapeutics
      • 10.3.2.1. Drug Description
      • 10.3.2.2. Pre-Clinical results
      • 10.3.2.3. Other development activities
      • 10.3.2.4. Product Profile

To be continued in the report…

11. Therapeutic Assessment

  • 11.1. Assessment by Monotherapy Products
  • 11.2. Assessment by Combination Products
  • 11.3. Assessment by Route of Administration
  • 11.4. Assessment by Stage and Route
  • 11.5. Assessment by Molecule Type
  • 11.6. Assessment by Stage and Molecule Type
  • 11.7. Assessment by Domain
  • 11.8. Assessment by Stage and Domain

12. Transthyretin Amyloidosis: Market Analysis

  • 12.1. Transthyretin Amyloidosis: 7 Major Market Outlook
    • 12.1.1. Market size of Transthyretin Amyloidosis in 7MM
    • 12.1.2. Therapy Based Market size of Transthyretin Amyloidosis in 7MM

13. Market Outlook by Country

  • 13.1. Transthyretin Amyloidosis: United States Market Analysis
    • 13.1.1. United States Market size
    • 13.1.2. Therapy-Based Market Size of Transthyretin Amyloidosis
  • 13.2. Transthyretin Amyloidosis: EU5 Market Analysis
    • 13.2.1. Germany
      • 13.2.1.1. Germany Market size
      • 13.2.1.2. Therapy Based Market Size of Transthyretin Amyloidosis
    • 13.2.2. France
      • 13.2.2.1. France Market size
      • 13.2.2.2. Therapy Based Market Size of Transthyretin Amyloidosis
    • 13.2.3. United Kingdom
      • 13.2.3.1. United Kingdom Market size
      • 13.2.3.2. Therapy Based Market Size of Transthyretin Amyloidosis
    • 13.2.4. Spain
      • 13.2.4.1. Spain Market size
      • 13.2.4.2. Therapy Based Market Size of Transthyretin Amyloidosis
    • 13.2.5. Italy
      • 13.2.5.1. Italy Market size
      • 13.2.5.2. Therapy Based Market Size of Transthyretin Amyloidosis
  • 13.3. Transthyretin Amyloidosis: Japan Market Analysis
    • 13.3.1. Japan Market size
    • 13.3.2. Therapy Based Market Size of Transthyretin Amyloidosis

14. Market Drivers

15. Market Barriers

16. Appendix

17. Report Methodology

  • 17.1. Sources Used

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight

List of Tables

  • Table 1 Diagnosed Prevalent Population of ATTR in 7MM (2015-2027)
  • Table 2 7MM-Type Specific Diagnosed Prevalent Population of ATTR (2015-2027)
  • Table 3 Diagnosed Prevalent Population of ATTR in US (2015-2027)
  • Table 4 Type-specific Diagnosed Prevalent Population of ATTR in US (2015-2027)
  • Table 5 Treatable cases of Transthyretin Amyloidosis (ATTR) in UK (2015-2027)
  • Table 6 Diagnosed Prevalent Population of ATTR in UK (2015-2027)
  • Table 7 Type-specific Diagnosed Prevalent Population of ATTR in UK (2015-2027)
  • Table 8 Treatable cases of Transthyretin Amyloidosis (ATTR) in UK (2015-2027)
  • Table 9 Diagnosed Prevalent Population of ATTR in Germany (2015-2027)
  • Table 10 Type-specific Diagnosed Prevalent Population of ATTR in Germany (2015-2027)
  • Table 11 Treatable cases of Transthyretin Amyloidosis (ATTR) in Germany (2015-2027)
  • Table 12 Diagnosed Prevalent Population of ATTR in Italy (2015-2027)
  • Table 13 Type-specific Diagnosed Prevalent Population of ATTR in Italy (2015-2027)
  • Table 14 Treatable cases of Transthyretin Amyloidosis (ATTR) in Italy (2015-2027)
  • Table 15 Diagnosed Prevalent Population of ATTR in Spain (2015-2027)
  • Table 16 Type-specific Diagnosed Prevalent Population of ATTR in Spain (2015-2027)
  • Table 17 Treatable cases of Transthyretin Amyloidosis (ATTR) in Spain (2015-2027)
  • Table 18 Diagnosed Prevalent Population of ATTR in France (2015-2027)
  • Table 19 Type-specific Diagnosed Prevalent Population of ATTR in France (2015-2027)
  • Table 20 Treatable cases of Transthyretin Amyloidosis (ATTR) in France (2015-2027)
  • Table 21 Diagnosed Prevalent Population of ATTR in Japan (2015-2027)
  • Table 22 Type-Specific Diagnosed Prevalent Population of ATTR in Japan (2015-2027)
  • Table 23 Treatable cases of Transthyretin Amyloidosis (ATTR) in Japan (2015-2027)
  • Table 24 7MM Diagnosed Prevalent and Surgery Cases of ATTR related Carpal Tunnel Syndrome (2015-2027)
  • Table 25 Diagnosed Prevalent and Surgery Cases of ATTR related Carpal Tunnel Syndrome in US (2015-2027)
  • Table 26 Diagnosed Prevalent and Surgery Cases of ATTR related Carpal Tunnel Syndrome in UK (2015-2027)
  • Table 27 Diagnosed Prevalent and Surgery Cases of ATTR related Carpal Tunnel Syndrome in Germany (2015-2027)
  • Table 28 Diagnosed Prevalent and Surgery Cases of ATTR related Carpal Tunnel Syndrome in Italy (2015-2027)
  • Table 29 Diagnosed Prevalent and Surgery Cases of ATTR related Carpal Tunnel Syndrome in Spain (2015-2027)
  • Table 30 Diagnosed Prevalent and Surgery Cases of ATTR related Carpal Tunnel Syndrome in France (2015-2027)
  • Table 31 Diagnosed Prevalent and Surgery Cases of ATTR related Carpal Tunnel Syndrome in Japan (2015-2027)
  • Table 32 Tafamidis, Clinical Trial Description, 2018
  • Table 33 Patisiran, Clinical Trial Description, 2018
  • Table 34 Inotersen , Clinical Trial Description, 2018
  • Table 35 CRX-1008, Clinical Trial Description, 2018
  • Table 36 Clinical Stage Products, 2018
  • Table 37 Pre-Clinical Stage Products, 2018
  • Table 38 Assessment by Monotherapy Products, 2018
  • Table 39 Assessment by Combination Products, 2018
  • Table 40 Assessment by Route Of Administration, 2018
  • Table 41 Assessment by Stage and Route Of Administration, 2018
  • Table 42 Assessment by Molecule Type, 2018
  • Table 43 Assessment by Stage and Molecule Type, 2018
  • Table 44 Assessment by Stage of development and Domain, 2018
  • Table 45 7 Major Market Size of Transthyretin Amyloidosis in USD Million (2015-2027)
  • Table 46 7 Major Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2027)
  • Table 47 7 Major Type Specific Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2027)
  • Table 48 Market Size of Transthyretin Amyloidosis in the United States, USD Millions (2015 -2027)
  • Table 49 Type Specific Market Size of Transthyretin Amyloidosis in the United States, USD Millions (2015 -2027)
  • Table 50 Therapy-Wise Market Size of Transthyretin Amyloidosis in the United States, USD Millions (2015 -2027)
  • Table 51 United States Type Specific Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2027)
  • Table 52 Market Size of Transthyretin Amyloidosis in the Germany, USD Millions (2015 -2027)
  • Table 53 Type Specific Market Size of Transthyretin Amyloidosis in Germany, USD Millions (2015 -2027)
  • Table 54 Therapy-Wise Market Size of Transthyretin Amyloidosis in Germany, USD Millions (2015 -2027)
  • Table 55 Germany Type Specific Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2027)
  • Table 56 Market Size of Transthyretin Amyloidosis in France, USD Millions (2015 -2027)
  • Table 57 Type Specific Market Size of Transthyretin Amyloidosis in France, USD Millions (2015 -2027)
  • Table 58 Therapy-Wise Market Size of Transthyretin Amyloidosis in France, USD Millions (2015 -2027)
  • Table 59 France Type Specific Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2027)
  • Table 60 Market Size of Transthyretin Amyloidosis in the United Kingdom, USD Millions (2015 -2027)
  • Table 61 Type Specific Market Size of Transthyretin Amyloidosis in the United Kingdom, USD Millions (2015 -2027)
  • Table 62 Therapy-Wise Market Size of Transthyretin Amyloidosis in the United Kingdom, USD Millions (2015 -2027)
  • Table 63 United Kingdom Type Specific Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2027)
  • Table 64 Market Size of Transthyretin Amyloidosis in Spain, USD Millions (2015 -2027)
  • Table 65 Type Specific Market Size of Transthyretin Amyloidosis in Spain, USD Millions (2015 -2027)
  • Table 66 Therapy-Wise Market Size of Transthyretin Amyloidosis in Spain, USD Millions (2015 -2027)
  • Table 67 Spain Type Specific Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2027)
  • Table 68 Market Size of Transthyretin Amyloidosis in Italy, USD Millions (2015 -2027)
  • Table 69 Type Specific Market Size of Transthyretin Amyloidosis in Italy, USD Millions (2015 -2027)
  • Table 70 Therapy-Wise Market Size of Transthyretin Amyloidosis in Italy, USD Millions (2015 -2027)
  • Table 71 Italy Type Specific Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2027)
  • Table 72 Market Size of Transthyretin Amyloidosis in Japan, USD Millions (2015 -2027)
  • Table 73 Type Specific Market Size of Transthyretin Amyloidosis in Japan, USD Millions (2015 -2027)
  • Table 74 Therapy-Wise Market Size of Transthyretin Amyloidosis in Japan, USD Millions (2015 -2027)
  • Table 75 Japan Type Specific Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2027)

List of Figures

  • Figure 1 Diagnosed Prevalent Population of ATTR in 7MM (2015-2027)
  • Figure 2 7MM-Type Specific Diagnosed Prevalent Population of ATTR (2015-2027)
  • Figure 3 Diagnosed Prevalent Population of ATTR in US (2015-2027)
  • Figure 4 Type-specific Diagnosed Prevalent Population of ATTR in US (2015-2027)
  • Figure 5 Treatable cases of Transthyretin Amyloidosis (ATTR) in UK (2015-2027)
  • Figure 6 Diagnosed Prevalent Population of ATTR in UK (2015-2027)
  • Figure 7 Type-specific Diagnosed Prevalent Population of ATTR in UK (2015-2027)
  • Figure 8 Treatable cases of Transthyretin Amyloidosis (ATTR) in UK (2015-2027)
  • Figure 9 Diagnosed Prevalent Population of ATTR in Germany (2015-2027)
  • Figure 10 Type-specific Diagnosed Prevalent Population of ATTR in Germany (2015-2027)
  • Figure 11 Treatable cases of Transthyretin Amyloidosis (ATTR) in Germany (2015-2027)
  • Figure 12 Diagnosed Prevalent Population of ATTR in Italy (2015-2027)
  • Figure 13 Type-specific Diagnosed Prevalent Population of ATTR in Italy (2015-2027)
  • Figure 14 Treatable cases of Transthyretin Amyloidosis (ATTR) in Italy (2015-2027)
  • Figure 15 Diagnosed Prevalent Population of ATTR in Spain (2015-2027)
  • Figure 16 Type-specific Diagnosed Prevalent Population of ATTR in Spain (2015-2027)
  • Figure 17 Treatable cases of Transthyretin Amyloidosis (ATTR) in Spain (2015-2027)
  • Figure 18 Diagnosed Prevalent Population of ATTR in France (2015-2027)
  • Figure 19 Type-specific Diagnosed Prevalent Population of ATTR in France (2015-2027)
  • Figure 20 Treatable cases of Transthyretin Amyloidosis (ATTR) in France (2015-2027)
  • Figure 21 Diagnosed Prevalent Population of ATTR in Japan (2015-2027)
  • Figure 22 Type-Specific Diagnosed Prevalent Population of ATTR in Japan (2015-2027)
  • Figure 23 Treatable cases of Transthyretin Amyloidosis (ATTR) in Japan (2015-2027)
  • Figure 24 7MM Diagnosed Prevalent and Surgery Cases of ATTR related Carpal Tunnel Syndrome (2015-2027)
  • Figure 25 Diagnosed Prevalent and Surgery Cases of ATTR related Carpal Tunnel Syndrome in US (2015-2027)
  • Figure 26 Diagnosed Prevalent and Surgery Cases of ATTR related Carpal Tunnel Syndrome in UK (2015-2027)
  • Figure 27 Diagnosed Prevalent and Surgery Cases of ATTR related Carpal Tunnel Syndrome in Germany (2015-2027)
  • Figure 28 Diagnosed Prevalent and Surgery Cases of ATTR related Carpal Tunnel Syndrome in Italy (2015-2027)
  • Figure 29 Diagnosed Prevalent and Surgery Cases of ATTR related Carpal Tunnel Syndrome in Spain (2015-2027)
  • Figure 30 Diagnosed Prevalent and Surgery Cases of ATTR related Carpal Tunnel Syndrome in France (2015-2027)
  • Figure 31 Diagnosed Prevalent and Surgery Cases of ATTR related Carpal Tunnel Syndrome in Japan (2015-2027)
  • Figure 32 Tafamidis, Clinical Trial Description, 2018
  • Figure 33 Patisiran, Clinical Trial Description, 2018
  • Figure 34 Inotersen , Clinical Trial Description, 2018
  • Figure 35 CRX-1008, Clinical Trial Description, 2018
  • Figure 36 Clinical Stage Products, 2018
  • Figure 37 Pre-Clinical Stage Products, 2018
  • Figure 38 Assessment by Monotherapy Products, 2018
  • Figure 39 Assessment by Combination Products, 2018
  • Figure 40 Assessment by Route Of Administration, 2018
  • Figure 41 Assessment by Stage and Route Of Administration, 2018
  • Figure 42 Assessment by Molecule Type, 2018
  • Figure 43 Assessment by Stage and Molecule Type, 2018
  • Figure 44 Assessment by Stage of development and Domain, 2018
  • Figure 45 7 Major Market Size of Transthyretin Amyloidosis in USD Million (2015-2027)
  • Figure 46 7 Major Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2027)
  • Figure 47 7 Major Type Specific Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2027)
  • Figure 48 Market Size of Transthyretin Amyloidosis in the United States, USD Millions (2015 -2027)
  • Figure 49 Type Specific Market Size of Transthyretin Amyloidosis in the United States, USD Millions (2015 -2027)
  • Figure 50 Therapy-Wise Market Size of Transthyretin Amyloidosis in the United States, USD Millions (2015 -2027)
  • Figure 51 United States Type Specific Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2027)
  • Figure 52 Market Size of Transthyretin Amyloidosis in the Germany, USD Millions (2015 -2027)
  • Figure 53 Type Specific Market Size of Transthyretin Amyloidosis in Germany, USD Millions (2015 -2027)
  • Figure 54 Therapy-Wise Market Size of Transthyretin Amyloidosis in Germany, USD Millions (2015 -2027)
  • Figure 55 Germany Type Specific Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2027)
  • Figure 56 Market Size of Transthyretin Amyloidosis in France, USD Millions (2015 -2027)
  • Figure 57 Type Specific Market Size of Transthyretin Amyloidosis in France, USD Millions (2015 -2027)
  • Figure 58 Therapy-Wise Market Size of Transthyretin Amyloidosis in France, USD Millions (2015 -2027)
  • Figure 59 France Type Specific Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2027)
  • Figure 60 Market Size of Transthyretin Amyloidosis in the United Kingdom, USD Millions (2015 -2027)
  • Figure 61 Type Specific Market Size of Transthyretin Amyloidosis in the United Kingdom, USD Millions (2015 -2027)
  • Figure 62 Therapy-Wise Market Size of Transthyretin Amyloidosis in the United Kingdom, USD Millions (2015 -2027)
  • Figure 63 United Kingdom Type Specific Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2027)
  • Figure 64 Market Size of Transthyretin Amyloidosis in Spain, USD Millions (2015 -2027)
  • Figure 65 Type Specific Market Size of Transthyretin Amyloidosis in Spain, USD Millions (2015 -2027)
  • Figure 66 Therapy-Wise Market Size of Transthyretin Amyloidosis in Spain, USD Millions (2015 -2027)
  • Figure 67 Spain Type Specific Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2027)
  • Figure 68 Market Size of Transthyretin Amyloidosis in Italy, USD Millions (2015 -2027)
  • Figure 69 Type Specific Market Size of Transthyretin Amyloidosis in Italy, USD Millions (2015 -2027)
  • Figure 70 Therapy-Wise Market Size of Transthyretin Amyloidosis in Italy, USD Millions (2015 -2027)
  • Figure 71 Italy Type Specific Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2027)
  • Figure 72 Market Size of Transthyretin Amyloidosis in Japan, USD Millions (2015 -2027)
  • Figure 73 Type Specific Market Size of Transthyretin Amyloidosis in Japan, USD Millions (2015 -2027)
  • Figure 74 Therapy-Wise Market Size of Transthyretin Amyloidosis in Japan, USD Millions (2015 -2027)
  • Figure 75 Japan Type Specific Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2027)